Paragraf Acquires Cardea Bio

QIAGEN to Acquire Parse Biosciences

November 4, 2025

Biotechnology

QIAGEN entered into a definitive agreement to fully acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell sequencing market. The deal is expected to close in late 2025/December 2025 for an upfront payment of approximately $225 million in cash, plus up to $55 million in milestone payments.

Carbon Acquires ParaMatters

August 24, 2022

Software

Carbon, the Redwood City-based 3D printing technology company, acquired ParaMatters to expand its generative design and topology-optimization software capabilities for additive manufacturing. The acquisition integrates ParaMatters’ design automation tools into Carbon’s idea-to-production platform to accelerate creation and production of higher-performance end-use parts.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

Cirtec Medical Acquires Cardea Catheter Innovations

July 26, 2021

Medical Devices

Cirtec Medical has acquired Cardea Catheter Innovations, a San Jose-based manufacturer of minimally invasive catheter devices and complex delivery systems. Cardea will integrate into Cirtec's NovelCath brand to expand the company's interventional capabilities across structural heart, electrophysiology, and neurovascular markets and will relocate into Cirtec's new San Jose Center of Excellence.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Catalent Acquires Paragon Bioservices for $1.2 Billion

May 20, 2019

Biotechnology

Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.